INDUSTRY NEWS

001-VN-Jul-2020

Real-world evidence (RWE) market worth over £1bn by 2023

  • Oncology segment accounted for the largest share of the RWE solutions market in 2017
  • The rising focus on end-to-end RWE services and growth within emerging markets are expected to provide further business opportunities for players operating in the RWE market

Click here to learn more

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

ref: JUL2020VN001